Compare WFCF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFCF | IFRX |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | Germany |
| Employees | 100 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.3M | 60.6M |
| IPO Year | 2006 | 2017 |
| Metric | WFCF | IFRX |
|---|---|---|
| Price | $12.14 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.3K | ★ 187.2K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $20,774,416.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $40.47 | ★ N/A |
| Revenue Growth | ★ 16.69 | N/A |
| 52 Week Low | $9.69 | $0.71 |
| 52 Week High | $13.70 | $1.94 |
| Indicator | WFCF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.77 | 49.69 |
| Support Level | $11.90 | $0.75 |
| Resistance Level | $12.31 | $1.16 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 28.57 | 38.89 |
Where Food Comes From Inc is a third-party food verification company conducting both on-site and desk audits to verify that claims being made about livestock, food, other high-value specialty crops and agricultural and aquaculture products are accurate. The company supports farmers, ranchers, vineyards, wineries, processors, retailers, distributors, trade associations, and restaurants with a wide variety of value-added services provided through its family of verifiers, including International Certification Services, Validus Verification Services, and others. It also provides a wide range of professional consulting services. It generates the majority of its revenue from Verification and certification services.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.